1 5 9 9 a r t I C l e S Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease accompanied by demyelination of the CNS. As a multifactorial, heterogeneous disease, MS is difficult to treat. Some patients with MS show CNS axonal damage, which may occur independently of chronic demyelination 1 . Disease heterogeneity also extends to drug response. For example, IFNβ, a first-line treatment for MS for over 15 years in relapsing-remitting MS (RRMS), is not effective in 7-49% of patients with RRMS 2 . Mechanisms underlying the heterogeneity in the disease etiology and patients' responses to treatments are largely unknown.
a r t I C l e S Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease accompanied by demyelination of the CNS. As a multifactorial, heterogeneous disease, MS is difficult to treat. Some patients with MS show CNS axonal damage, which may occur independently of chronic demyelination 1 . Disease heterogeneity also extends to drug response. For example, IFNβ, a first-line treatment for MS for over 15 years in relapsing-remitting MS (RRMS), is not effective in 7-49% of patients with RRMS 2 . Mechanisms underlying the heterogeneity in the disease etiology and patients' responses to treatments are largely unknown.
Experimental autoimmune encephalomyelitis (EAE), an animal model of MS, has provided insight into some of the pathological mechanisms of MS and has led to the development of glatiramer acetate and natalizumab as therapeutics [3] [4] [5] . However, there is an inherent challenge in using EAE as a model for studying disease heterogeneity without introducing confounding factors such as an alternative mouse strains, manipulating gene expression, or using unconventional reagents 6 .
The NLRP3 inflammasome is a crucial target of IFNβ treatment in EAE. We have previously reported that IFNβ suppresses NLRP3 inflammasome activity by reducing active Rac-1 and mitochondrial generation of reactive oxygen species 7 . The NLRP3 inflammasome is critical in EAE development, as demonstrated by the resistance of Nlrp3 −/− mice to EAE 8, 9 . The lack of the NLRP3 inflammasome in antigen-presenting cells dampens expression of chemokines and chemokine receptors on T helper cells and antigen-presenting cells, and prevents their migration to the CNS 8 . Nevertheless, it is also known that EAE can develop without the NLRP3 inflammasome 7, 10 . The alternative mechanistic pathway by which EAE is induced without the NLRP3 inflammasome, however, is elusive, and it is unknown whether the NLRP3 inflammasome-independent EAE is functionally and phenotypically distinct from typical NLRP3 inflammasome-dependent EAE. Understanding these mechanisms may represent a pivotal step toward understanding heterogeneity in EAE, and possibly in MS too.
In this study, we sought to reveal the molecular and cellular mechanisms that govern the pathophysiology of type B EAE by dissecting the mechanisms behind an NLRP3 inflammasome-independent EAE subtype that is induced by aggressive immunization using high doses of heat-killed mycobacteria (Mtb) without introducing confounding factors, such as the use of genetically modified mice or additional reagents in immunization. For type B EAE development, our results suggest the critical involvement and enhanced expression of lymphotoxin-β receptor (LTβR) and the chemokine receptor CXCR2, which detect membrane-bound lymphotoxin (mLT) and the chemokine CXCL1, respectively. The pathway including LTβR and CXCR2 allows mice to bypass NLRP3 inflammasome-mediated inflammation for EAE induction. Although type B EAE does not respond to IFNβ treatment, blockade of LTβR or CXCR2 successfully ameliorated the disease. Furthermore, relative levels of Ltbr and Cxcr2 were increased in patients with IFNβ-resistant RRMS. Type B EAE was found to be irreversible as a result of the neuronal damage mediated by semaphorin 6B (Sema6B) upregulation in CD4 + T cells in the CNS. 
NLRP3 is dispensable for EAE induced by high adjuvant doses
We titrated the amounts of Mtb (adjuvant) used in complete Freund's adjuvant (CFA) to induce EAE, and evaluated disease severity in Nlrp3 −/− mice in the C57BL6 background. We chose Nlrp3 −/− mice because they developed very mild EAE using the standard EAE induction method with 200 µg Mtb in CFA (method 1 in Supplementary  Fig. 1a,b) , as previously reported 8 . However, either repeated immunization or an increased Mtb dosage (400 µg) was sufficient to induce severe EAE in Nlrp3 −/− mice (methods 2 and 3 in Supplementary  Fig. 1a,b) . In contrast, a 25% increase in myelin oligodendrocyte glycoprotein (MOG) peptide did not change EAE severity (methods 3 vs. 4 and 5 vs. 6 in Supplementary Fig. 1a,b) . Using the most aggressive EAE induction method (method 6 in Supplementary Fig. 1a,b) , Asc −/− and Nlrp3 −/− mice developed a comparable disease severity to that in wild-type (WT) mice (Fig. 1a) , as well as similar numbers of total leukocytes, CD4 + T cells, and IL-17-producing T helper (T H 17) cells in spinal cords and brains (Fig. 1b,c and Supplementary Fig. 1c) . Notably, EAE induced by method 6 completely abrogated the efficacy of IFNβ both in WT and Nlrp3 −/− mice ( Fig. 1d and Supplementary  Fig. 1d ). We termed this EAE subtype, which develops without the NLRP3 inflammasome and does not respond to IFNβ, "type B EAE," in contrast to the EAE subtype induced by method 1, which is NLRP3 inflammasome dependent and responds to IFNβ treatment (termed "type A EAE") ( Fig. 1d) . Type B EAE mice could not be clinically distinguished from type A EAE mice for the first 30 d in either body weight (Supplementary Fig. 1e ) or ataxia ( Supplementary Videos 1 and 2) . The results here also suggested that there are intermediate phenotypes, at least in disease severity in Nlrp3 −/− mice, that represent a continuum of the EAE subtypes.
Type B EAE mice were characterized with low, basal levels of serum interleukin (IL)-1β (Fig. 1e) . Despite high expression of Il1b mRNA, splenocytes from type B EAE mice showed significantly decreased ability to produce mature and secreted IL-1β (P = 0.0261) as a result of decreased caspase-1 activity (P = 0.0020) compared to those from type A EAE mice ( Supplementary Fig. 1f-h) . The results strongly suggest low levels of NLRP3 inflammasome activation in type B EAE. In contrast, high levels of serum IFNβ were observed in type B EAE mice (Fig. 1f) . As IFNβ suppresses NLRP3 inflammasome activity 7 , endogenous IFNβ may contribute to inhibiting NLRP3 inflammasome activation in type B EAE mice.
Because type B EAE is induced with high dosages of adjuvant (Mtb), we sought to determine whether acute infection would convert the phenotype of mice immunized with the type A EAE induction protocol to a type B EAE response. Here we intentionally used an agent other than Mtb to ensure that our hypothesis-strong stimulation of innate immunity enhances type B EAE responses-is not specific to the Mtb adjuvant. We chose murine gamma herpesvirus-68 (MHV68), equivalent to Epstein-Barr virus (EBV) in humans, because of the relevance of EBV infection to MS 11 . Type A EAE induction accompanied by a high-dose inoculum of MHV68 caused mice to develop NLRP3 inflammasome-independent and IFNβ-resistant EAE (Fig. 1g) . Thus, it is possible that EAE is skewed toward type B by strong stimulation of innate immunity with high dosages of adjuvant or acute infection.
Distinct phenotypes between type A and type B EAE Type B EAE mice showed significantly higher numbers of various leukocytes in the brain than type A EAE mice at 17 d post-immunization (dpi), the peak time of disease ( Fig. 1h and Supplementary Fig. 1i ). In contrast, type A EAE mice showed higher numbers of these cells in the spinal cord than type B EAE mice ( Fig. 1h and Supplementary  Fig. 1i ). Type B EAE mice showed mild demyelination in the spinal cord, whereas demyelination in type A EAE mice was severe (Fig. 1i) . Conversely, type B EAE mice, but not type A EAE mice, suffered severe demyelination near the choroid plexus (an entry route of immune cells into the brain 12 ) and in the optic nerve (Fig. 1i, Supplementary  Fig. 1j ). Magnetic resonance imaging (MRI) T2 fluid-attenuated inversion recovery (FLAIR) images showed hyperintensity, reflecting demyelination and cell density changes, in the external capsule and adjacent cortical regions in the brains of type B EAE mice at 18 dpi and to a lesser extent in the spinal cord ( Fig. 1j and Supplementary  Fig. 1k ). Type B EAE mice also showed thermal hyperalgesia at 9 dpi (before or around EAE onset) whereas mice with type A EAE did not (Supplementary Fig. 1l) Table 1) . Lta encodes lymphotoxin-α (LTα, also termed TNFβ), which forms a secreted homotrimer or a membranebound heterotrimer with LTβ (i.e., mLT). Lymphotoxin is known to be critical in the development of MS and EAE 13, 14 and was observed in demyelinated regions in the brain of some MS patients 15 and in their serum 16 . Blockade of LTβR, an mLT receptor, ameliorates EAE induced by repetitive immunizations 17 , a condition that might approximate type B EAE. Although Lta mRNA is widely known to be expressed in lymphocytes, DCs and macrophages expressed enhanced levels of Lta mRNA and mLT in type B EAE (Fig. 2a,b and Supplementary Fig. 2a,b) . Antigen was not required to induce mLT expression on DCs, as a high dose of Mtb in CFA was sufficient ( Supplementary Fig. 2c ), although the MOG antigen helped to further induce mLT expression in type B EAE (Fig. 2b) . These results suggest that strong stimulation of innate immunity with high dose of adjuvant alone is sufficient to induce LTα expression on DCs and macrophages (mLT expression).
Induction of Lta mRNA in DCs was, at least in part, attributable to epigenetic alteration of the Lta gene locus. We found that the Lta promoter in DCs from type B EAE mice was hypomethylated, compared to that of naive and type A EAE mice ( Fig. 2c and Supplementary Fig. 2d) . Notably, LTβR signaling is essential for development of type B EAE, because an LTβR antagonist, LTβR-Fc, ameliorated type B EAE, but not type A EAE (Fig. 2d) . We then hypothesized that recombinant lymphotoxin (rLT; LTα2β1), a soluble LTβR agonist, might convert the EAE phenotype from type A to the type B. With rLT treatment and type A EAE induction, Nlrp3 −/− mice developed severe EAE (Fig. 2e) and WT mice lost responsiveness to IFNβ treatment (Fig. 2f) . Moreover, rLT treatment increased immune cell migration into the brain (Fig. 2g) , as observed in type B EAE mice (Fig. 1h) . Taken together, these findings strongly suggest mLT and LTβR are key factors for type B EAE development.
Type B EAE and T H 17 cell-mediated passive EAE
A previous report showed that IFNβ treatment does not ameliorate passive EAE induced by T H 17 cell adoptive transfer 18 . We sought a © 2016 Nature America, Inc., part of Springer Nature. All rights reserved. Table 2 ). To further address the broad changes in gene expression profile in CD4 + T cells, we performed high-throughput RNA-seq analysis ( Fig. 3 and Supplementary Fig. 3 ), obtaining distinct gene expression profile between type A EAE and type B EAE (Fig. 3a) . There were 668 genes upregulated more than twofold (P < 0.05) in CD4 + T cells from type B EAE mice compared to those from type A EAE mice, while 600 were downregulated more than twofold. Several genes previously detected by PCR array, such as Cxcr2 a r t I C l e S and Cxcr1 (Supplementary Table 2 ), were consistently detected by RNA-seq as highly expressed in type B EAE. Notably, highly expressed genes in type B EAE included those that encode pattern-recognition receptors and neuronal damage-related molecules (Fig. 3c) , suggesting enhanced inflammation and neuronal damage in type B EAE. In CD4 + T cells from spleens of type B EAE mice, standard quantitative PCR (qPCR) confirmed the results from PCR array and RNAseq analyses of abundant expression of Cxcr2, Cxcr1 and Ltbr mRNA (Fig. 3d) . Expression of the genes in CD4 + T cells was induced by ex vivo rLT treatment (Fig. 3e) , suggesting that the upregulation of the mRNA in type B EAE was mediated by enhanced LTβR stimulation.
Comparison between type A and type B EAE
We next sought to identify differences between the two EAE subtypes at the cellular and protein levels. At the cellular level in peripheral lymphoid organs on day 9, numbers of T cells (total T, total CD4 + T, total CD8 + T, T helper type 1 (T H 1), T H 17, and regulatory T (T reg ) cells) and DCs were similar between two EAE subtypes; and numbers of total leukocytes and B cells were increased in type B EAE mice both in DLNs and spleens (Fig. 4a) . Around the disease peak time, B cells did not show differences in their numbers ( Supplementary  Fig. 4a) . We also examined proportions of granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing T H 1 and T H 17 cells in the spleen at 9 dpi because they are encephalitogenic 19, 20 , but no difference was found (Supplementary Fig. 4b,c) . T H 17 cell subsets expressing IFNγ, GM-CSF, IL-22, or CD5L in the spinal cord at 17 dpi also showed no difference in their population sizes between the two EAE subsets (Supplementary Fig. 4d ). These results suggested no marked alteration in leukocyte numbers in type B EAE.
We next focused on cell surface protein expression on leukocytes in secondary lymphoid organs. CXCR2 is known as a major chemokine receptor mainly on neutrophils. As expected, most neutrophils expressed CXCR2 in naive and both EAE subtypes, but mean fluorescent intensity was significantly increased (P (naive vs. type B) = 0.0014) in type B EAE (Supplementary Fig. 4e ). In contrast, CD4 + T cells are not largely known to express CXCR2. Nevertheless, more than 10% of CD4 + T cells from type B EAE mice expressed CXCR2 on their cell surface ( Fig. 4b and Supplementary Fig. 4f) . In addition, CXCR2 + macrophages were also more frequent and expressed higher levels of CXCR2 in type B EAE (Supplementary Fig. 4e) . Thus, the data suggest that type B EAE induces CXCR2 in both lymphoid and myeloid cells.
Gene expression in PBMCs in IFNb-resistant RRMS
We next compared gene expression of CXCR2, CXCR1 and LTBR between patients with RRMS that responded vs. did not respond to IFNβ treatment by using peripheral blood mononuclear cells (PBMCs), which are mixtures of lymphocytes, monocytes and others. a r t I C l e S When expression levels relative to VCAM1 were calculated (VCAM1 is expressed in monocytes (EMBL-EBI Expression Atlas; https://www. ebi.ac.uk/gxa/home) and is not differentially expressed between IFNβ-responsive and resistant RRMS 21 ), the data showed that relative mRNA expression of CXCR2, CXCR1 and LTBR were elevated in PBMCs from patients who did not respond to IFNβ therapy (Fig. 4c) .
Two-thirds of patients with IFNβ-resistant RRMS showed comparable gene expression levels to patients who responded to IFNβ. It is possible that using total PBMCs averaged out the changes in CD4 + T cells; thus, further analyses using purified CD4 + T cells are required to directly evaluate gene expression. Coefficient of determination (R 2 ) values between relative expression levels of CXCR1 and LTBR were notably Figure 5 Involvement of the CXCL1 and CXCR2 in development of type B EAE and type A EAE with MHV68 infection. (a) Transwell migration assay toward rCXCL1 using splenic CD4 + T cells collected from indicated mice. n = 4. (b) Levels of CXCL1 in serum from naive mice or mice with type A or type B EAE mice at 9 dpi, determined by ELISA. Naive, n = 5; type A, n = 3; type B, n = 5. P (naive vs. type A) = 0.8676, t(6) = 0.174; P (naive vs. type B) = 0.0059, t(8) = 3.722; P (type A vs. type B) = 0.0334, t(6) = 2.749. (c) CXCL1 staining in the choroid plexus at 9 dpi. Scale bars, 20 µm. (d,e) Levels of CXCL1 in serum from type B EAE with or without LTβR-Fc treatment at 9 dpi. n = 4. P = 0.0174, t(6) = 3.252. Scale bars, 20 µm. (f) Score of type A or type B EAE treated with or without SB225002. Vehicle-treated group, n = 5; SB225002-treated group, n = 7. P = 0.002, t(10) = 5.634. (g) EAE score in Cxcr2 fl/fl Lck-cre + mice (CXCR2-cKO) and Cxcr2 fl/fl mice (control). *P < 0.05 (n = 8). P = 0.0192, t(14) = 2.646. (h) Representative Luxol fast blue-stained images at 17 dpi; red lines, regions of demyelination. Scale bars, 200 µm. (i) Percentages LTα + DCs in DLNs and CXCR2 + CD4 + T cells in spleens of mice at 9 dpi immunized with a type A EAE induction method with or without MHV68 infection (n = 4). P = 0.0002, t(6) = 7.72; P = 0.0026, t(6) = 4.931. (j) Serum IL-1β and CXCL1 at 9 dpi in naive mice and mice immunized with a type A EAE induction method, with or without MHV68 infection. n = 4. IL-1β: P (naive vs. type A) = 0.0152, t(6) = 3.361; P (naive vs. type A+MHV68) = 0.3925, t(6) = 0.9212; P (type A vs. type A+MHV68) = 0.0259, t(6) = 2.942. CXCL1: P (naive vs. type A) = 0.8498, t(6) = 0.1978; P (naive vs. type A+MHV68) = 0.0174, t(6) = 3.252; P (type A vs. type A+MHV68) = 0.0205, t(6) = 3.124. (k) EAE scores of type A-induced mice with MHV68 infection. Treatment was with either LTβR-Fc or SB225002. Negative control groups did not receive the treatments (n = 4). All statistical analyses in this figure were performed by two-tailed unpaired Student's t-test. *P < 0.05. All data and images are representative of at least 2 similar experiments for each. Error bars, s.e.m.
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VOLUME 19 | NUMBER 12 | DECEMBER 2016 nature neurOSCIenCe a r t I C l e S higher in patients with IFNβ-resistant MS (Supplementary Fig. 4g) . Taken together, the data suggested that relative expression of CXCR2, CXCR1 and LTBR might be used to distinguish IFNβ-resistant RRMS.
Critical role of CXCR2 in type B EAE As CD4 + T cells from type B EAE mice expressed high levels of CXCR2 ( Fig. 4b and Supplementary Fig. 4e) , the cells showed strong chemotaxis toward CXCL1, a ligand for CXCR2 (Fig. 5a) . Type B EAE produced high levels of CXCL1 in serum, choroid plexus, and the spinal cord (Fig. 5b,c and Supplementary Fig. 5 ). The CXCL1 levels in serum and choroid plexus in type B EAE mice were reduced by blocking LTβR in vivo (Fig. 5d,e) , suggesting enhancement of the CXCL1-CXCR2 axis by mLT in the development of type B EAE.
CXCR2 is indeed a key molecule specifically in type B EAE, as blockade of CXCR2 with SB225002 ameliorated type B EAE, but not type A EAE (Fig. 5f) . We confirmed the involvement of CXCR2 on T cells in vivo by using Cxcr2 fl/fl Lck-cre + (CXCR2 conditional knockout) mice, which lack CXCR2 in T cells. The lack of CXCR2 in T cells did not alter disease score in type A EAE. However, although mice with CXCR2 deficiency in T cells eventually developed severe type B EAE, onset was significantly slowed (Fig. 5g) . SB225002-treated mice and CXCR2 conditional knockout mice showed mild demyelination in the spinal cord at 17 dpi (Fig. 5h) . Thus, T cell CXCR2 is critical in type B EAE.
Virus infection switches the EAE phenotype from type A to type B
We have shown that a high-dose inoculum of MHV68 caused mice, despite type A induction, to develop NLRP3 inflammasomeindependent and IFNβ-resistant EAE (Fig. 1g) . MHV68 infection also increased CXCR2 + CD4 + T cells together with mLT-expressing DCs (Fig. 5i) . Furthermore, MHV68 infection converted mice with type A induction to type B EAE responses, such as reduced serum IL-1β levels and increased CXCL1 levels (Fig. 5j) , allowing infected mice, despite type A EAE induction, to respond to treatments that block LTβR or CXCR2 (Fig. 5k) . These results suggest strong stimulation of innate immunity triggers LTβR-CXCR2 axis to induce the type B EAE phenotype.
Minimum remission and neuronal damage in type B EAE mice
Type B EAE mice showed persistent EAE severity with little remission (Fig. 6a) . To investigate the long-term disease severity, we focused the spinal cord rather than the brain because the spinal cord is responsible for overt motor disability in EAE. Despite severe demyelination in spinal cord (Fig. 6b) , leukocyte infiltration was not clearly observed in the spinal cords in type B EAE mice ( Supplementary  Fig. 6a ) at a later stage of EAE, ~60-70 dpi. Thus, rather than sustained inflammation triggered by infiltrated leukocytes, we considered the possibility of poor remyelination to explain the sustained EAE phenotype. However, type B EAE mice did successfully express insulin-like growth factor (IGF)-1, a critical molecule in remyelination 22, 23 (Supplementary Fig. 6b) .
We next evaluated morphology of neurons in spinal cord sections from EAE mice because a previous study demonstrated the loss of neurites in some MS patients 24 . With Bielschowsky neuronal staining, we found that type B EAE mice showed fainter staining particularly in outer areas of the white matter, which may include the descending tracts (Supplementary Fig. 6c) . Furthermore, Golgi silver staining, which stains random subsets of neurons, revealed that type B EAE mice at 70 dpi showed low-density, transected neurites in the spinal ventral horn containing motor neurons (Fig. 6c) . Stereological analysis confirmed the significant reduction of α-motor neurons and interneurons surrounding α-motor neurons in the spinal ventral horn of type B EAE mice (Fig. 6d) . In contrast, type A EAE mice showed similar neuronal morphology and numbers of α-motor neurons to naive mice (Fig. 6c,d and Supplementary Fig. 6d) . At an earlier stage of EAE (22 dpi), some, but not marked, differences between type A and type B EAE Golgi staining was also identified ( Supplementary  Fig. 6e ). These result suggested that the minimal remission in type B EAE may be attributed to irreversible loss of axons in type B EAE.
Type B EAE CD4 + T cells induce neuronal retraction via Sema6B
To further investigate the altered neuronal morphology in type B EAE mice, we examined primary hippocampal neurons cocultured with CD4 + T cells from EAE mice. In neuron-T cell coculture, suppression of neurite outgrowth and reduction in the number of axon, dendrites, and branches were observed when using CD4 + T cells from type B EAE mice. However, the phenomenon was not seen with T cells from type A EAE mice (Fig. 7a) . Quantitative analyses confirmed decreased lengths of neurites and numbers of axon-dendrite branches with CD4 + T cells from type B EAE mice (Fig. 7b,c) .
To identify molecules responsible for transected neurites specific to type B EAE, we examined expression levels of axon guidance molecules in the semaphorin and ephrin families. Among several molecules that potently inhibit neurite outgrowth, Sema6B (a class 6 transmembrane semaphorin) 25 gene expression was particularly high in CD4 + T cells from type B EAE mice (Fig. 7d) . Knocking down Sema6b mRNA by short hairpin RNA (62% reduction of mRNA; Supplementary Fig. 7 ) in CD4 + T cells from type B EAE mice almost completely rescued neurite outgrowth (Fig. 7e,f) . Importantly, rLT treatment induced Sema6b mRNA expression in CD4 + T cells isolated from type A EAE mice (Fig. 7g) . rLT-treated CD4 + T cells potently shortened neurite (Fig. 7h) . In sum, these results suggested that Sema6B upregulation by LTβR signaling in CD4 + T cells enhances neurite retraction in type B EAE mice.
DISCUSSION
In this study, we demonstrate that strong activation of the innate immune system substantially influences the development of EAE and disease phenotype, i.e., high dosages of adjuvant (Mtb) were sufficient to induce a distinct subtype of EAE (summarized in Supplementary Fig. 8 ). This simple method enabled us to study the heterogeneity of EAE without introducing confounding factors such as special reagents, genomic mutations, mRNA knockdown, and mouse strains other than the commonly used C57BL/6. As an environmental cue representing strong activation of the innate immune system, we found that acute virus infection could mimic the effect of increased Mtb and convert type A EAE to type B EAE, leading to the failure of IFNβ treatment. The result suggests that intensity of infections could modulate autoimmune responses and possibly alter treatment options, at least in part. Type B EAE was distinct from type A EAE in three respects: increased recruitment of inflammatory cells in the brain, prolonged disease with neuronal damage, and differences in gene and protein expression profiles. Yet type B EAE pathology did not alter composition of major leukocyte subpopulations. Based on the gene and protein expression patterns between two EAE subtypes, development of type B EAE may inhibit development of type A EAE. For example, the high levels of endogenous IFNβ found in the type B EAE condition are believed to suppress NLRP3 inflammasome activity 7 , which is required for type A EAE. Type B EAE development depends on the mLT-LTβR axis. Type B EAE cannot be treated by IFNβ, but is ameliorated by an LTβR antagonist. Furthermore, rLT treatment switches type A EAE to type B EAE. We have not called type B EAE in this study "atypical EAE," a variant previously reported by a number of laboratories, because type B EAE mice do not show phenotypes of atypical EAE such as severe gait ataxia, hemiparesis, and extensive cellular infiltration in the cerebellum [26] [27] [28] [29] . It is of note that Liu et al. 27 also demonstrated that CXCR2 blockade ameliorates atypical EAE, and the CXCR2 blockade mechanism of atypical EAE was shown to work through neutrophils. By contrast, our data suggest that blocking CXCR2 on CD4 + T cells is critical to ameliorating type B EAE.
We have shown that rIL-17 induces Lta expression. Lta is highly expressed in type B EAE. In addition, LTβR blockade ameliorates both T H 17-mediated EAE and type B EAE. These results suggest that T H 17-mediated EAE and type B EAE share some common pathology. Previous reports showed that T H 17-mediated EAE is characterized by induced neuronal damage 30 and resistance to IFNβ treatment 18 . We also demonstrate that type B EAE is characterized by neuronal damage and resistance to IFNβ treatment.
Our results suggest that mLT expressed on DCs increases CXCR2 expression on CD4 + T cells, neutrophils and macrophages to induce type B EAE. In addition, mLT-mediated induction of CXCL1, as well as its receptor CXCR2, was shown to be critical for type B EAE induction. Although CXCR2 is widely known as a neutrophil receptor, we found that CD4 + T cells induce expression of CXCR2 in type B EAE, and CXCR2 on CD4 + T cells is essential for the early phase of type B EAE development. CXCR2 on CD4 + T cells has also been reported in other conditions, such as aging 31 , Alzheimer's disease 32 and tuberculosis 33 . We found that rLT treatment induces CXCR2 expression on CD4 + T cells in vivo, as well as serum CXCL1. A previous study showed that LTβR signaling is required for upregulation of CXCL1 expression in intestinal epithelial cells for neutrophil recruitment to a bacterial infection site 34 . The interplay between LTβR and the CXCL1-CXCR2 axis appears to be critical for inducing inflammation and is involved in the pathogenesis of type B EAE.
We found that PBMCs from patients whose RRMS did not respond to IFNβ showed elevated relative expression of CXCR2, CXCR1 and LTBR compared to PBMCs from patients who did respond. Although only PBMCs were available to this study, further analyses using purified CD4 + T cells from patients will be required to delineate pathogenic mechanisms involving CXCR1, CXCR2 and LTβR in MS and to evaluate whether type B EAE recapitulates the phenotype of IFNβ-resistant MS.
Type A and type B EAE have distinct phenotypes in the CNS. In particular, type B EAE shows minimal remission because it involves neuronal damage, which is irreversible and reminiscent of progressive MS, which shows no disease remission and involves neuronal damage 35, 36 . Regarding neuronal damage in type B EAE, we found that Sema6B generated by CD4 + T cells causes neurite retraction. Previous reports have demonstrated that Sema6B, detected by its receptors (plexin-A2 and plexin-A4), induces neuronal growth cone collapse and repulsion 25, [37] [38] [39] . This mechanism may be at work in Sema6B-dependent neurite retraction in type B EAE. Although there is no report of Sema6B in MS, other semaphorins have been reported to be altered in MS. Specifically, SEMA3A and SEMA3F transcripts are detected around and within demyelinating white matter lesions in MS 40 .
Our RNA-seq analysis identified genes highly expressed in CD4 + T cells from type B EAE mice. Some genes shown in Figure 3c are thought to be involved in neuronal damage. In particular, phospholipase A2, encoded by the Pla2g4a and Pla3g7 genes, induces neuronal damage in its secreted form 41, 42 . MGST1, encoded by Mgst1, also damages neurons by activating prostaglandin E synthase 43 . Alox5ap encodes the arachidonate 5-lipoxygenase (ALOX5) activating protein, which facilitates leukotriene biosynthesis: ALOX5 and leukotriene are detected in MS lesions and cerebrospinal fluid from MS patients, respectively 44, 45 , and contribute to axonal damage 46 . The RNA-seq analysis did not detect Sema6b, because its expression levels were not abundant enough to draw a conclusion with this approach. Yet induction of Sema6b mRNA was detected in CD4 + T cells from type B EAE mice by standard qPCR.
Here we report that strong activation of innate immunity makes the EAE pathological mechanism bypass the NLRP3 inflammasome and that the EAE subtype developed without the NLRP3 inflammasome (i.e., type B EAE) shows distinct mechanisms in disease development and responses to drug treatment. Although further studies are required to answer whether the type A-type B EAE spectrum recapitulates the heterogeneity in MS at least to some extent, elucidating mechanisms to generate heterogeneity in EAE may provide new molecular insights in developing prognostic indicators and treatments of MS as a heterogeneous disease.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. (15 female and 3 male) per group. Ages of patients varied from 23 to 64 years old in the responsive group (mean of 47.0 years old, s.d. of 11.429; the age of one patient was unknown) and from 26 to 68 years old in the resistant group (mean of 47.8 years old, s.d. of 10.837). RNA from the responsive and resistant groups was quantified via Ribogreen, normalized and converted to cDNA using the SuperScript VILO cDNA Synthesis kit. Gene expression assays used the TaqMan Gene Expression protocol and were run on the ViiA 7 Real-Time PCR System. dnA methylation assay. DCs were FACS-sorted as CD11c + CD11b − from DLNs of naive and EAE mice at 9 dpi. Genomic DNA was obtained with the GenElute Mammalian Genomic DNA Miniprep kit (Sigma). Bisulfite conversion was performed with the MethylDetector kit (Active Motif), and the Lta promoter (between −363 and +65 nt from the transcription start site) was cloned into the pCR4-TOPO-TA vector (Life Technologies) and transformed into E. coli. Methylation status was evaluated by sequencing 17-22 clones per group. Percentages of unmethylated CpG in all tested CpG sites were calculated.
Analyzing demyelination. For Luxol fast blue staining, transverse sections (5 µm) of spinal cord and brain from mice were stained at 17 dpi. MRI analysis was performed on brains from mice with either type A or type B EAE at 18 dpi. For MRI, 10% buffered formalin-perfused mouse brains were kept within the cranium to prevent any potential damage to the brain caused by surgical removal. All images were acquired using a 9.4 T (400 MHz) 89-mm vertical bore Oxford magnet with shielded coil providing gradients of 2,200 mT/m. The system was controlled by the Agilent imaging console. The specimens were scanned using a 2D fluid-attenuated inversion recovery (FLAIR) sequence with the following parameters: FOV = 22 × 11 mm 2 , matrix = 256 × 128, 0.5 mm slice thickness with zero gap, TR/TI/TE = 5,000/925/30.8 ms, echo train length = 8, bandwidth = 100 kHz, 12 averages. neuronal staining and motor neuron analysis by stereology. Neuronal staining was performed by Golgi's silver staining with the FD Rapid Golgi staining kit (FD Neurotechnologies, Inc.) and Bielschowsky staining with Hito Bielschowsky OptimStain Kit (Hito Biotec) according manufacture's protocol. For stereological analysis, 4% paraformaldehyde-fixed spinal cords were removed from EAE mice at 70 dpi. Tissue sections (30 µm) were analyzed by stereology using Stereo Investigator v11 (MicroBrightfield, Williston, VT) using a Zeiss AxioImager M2 microscope. Contours were drawn around the ventral horn with a 5× objective and neuronal counting was completed using a 63×, 1.40 oil objective (Zeiss). Beginning at L6 and moving caudally, we sampled 10 lumbar spinal sections at a section interval of 5. Using the resample oversample tool in Stereo Investigator, we first determined that, at a section interval of 5, a systematic random sampling (SRS) grid size of 164 × 90 would allow precise cell estimates in the ventral horn of the lumbar region. The mounted thickness was 22 µm after tissue shrinkage and we used 2-µm guard zones. The dissector height was 18 µm and the counting frame size was 75 × 75 µm. Stereology parameters are indicated in Supplementary  Table 4 . The total numbers of bilateral Nissl-stained ventral horn neurons were counted stereologically with the Stereo Investigator software by using an optical fractionator. α-motor neurons were defined by having a maximum diameter greater than 30 µm. The average number of α-motor neurons (>30 µm) was 162. The average number of total Nissl-stained neurons counted per animal was 337. Our analysis produced a CE (Gunderson, m = 1) of 0.078. cd4 + T cell-neuron coculture and neurite length measurement. Primary neurons were obtained from the hippocampus of P2 mice as previously described 58 . After papain treatment of hippocampal tissue, 1 × 10 5 cells were cultured for 8 d. Splenic CD4 + T cells were isolated with CD4 microbeads (Miltenyi) and cultured with neurons for 24 h. Neuron and nuclear staining were performed with MAP2 and DAPI, respectively. Neurite lengths and numbers of total axons, dendrites and branches were analyzed with Neurolucida software (MBF Bioscience) using at least 18 neurons per condition.
Hot plate test.
To evaluate thermal sensitivity, a hot plate test 59 (52 °C and 40-s cut-off) was used for mice at 9 dpi during the light cycle (daytime). chemotaxis assay. As previously described 8 , splenic CD4 + T cells (1 × 10 6 cells per well) obtained from naive mice or EAE mice at 9 dpi were plated in upper chambers of Transwell chambers (5 µm pore, Corning Costar). rCXCL1 was added to lower chambers, and cells were incubated for 3 h at 37 °C. Numbers of migrated cell were counted, and the data are displayed after subtracting cell numbers in lower chambers in an untreated group as control.
Statistical analysis. Statistical analysis in all results, except for human sample analysis and for motor neuron stereology analysis, was evaluated with twotailed unpaired Student's t tests and t-values. The criterion of significance was set as P < 0.05. Statistical analysis for human samples was carried out with the Mann-Whitney U test. Differences among means in motor neuron stereology analysis were analyzed by one-way ANOVA followed by Bonferroni post hoc testing for pairwise comparison unless otherwise stated. Animals were randomly used for experiments under the criteria aforementioned in the section "Animals. " All behavior experiments were performed in a blinded fashion. No animals or data points were excluded. Quantifications were performed from at least two experimental groups in a blinded fashion. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those generally employed in the field. Data distribution was assumed to be normal, but this was not formally tested. Blinding and randomization was performed in all experiments.
A Supplementary methods checklist is available.
data availability. The RNA-seq data have been deposited in the NCBI Gene Expression Omnibus (GEO) under accession code GSE85946. The data that support the findings of this study are available from the corresponding author upon reasonable request.
